[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619702":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":11,"id":55,"slug":11,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"GR1803 injection dose 1","EXPERIMENTAL",null,[13],"Biological: GR1803 injection",{"label":15,"type":10,"description":11,"interventionNames":16},"GR1803 injection dose 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"GR1803 injection dose 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"GR1803 injection dose 4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"BIOLOGICAL","GR1803 injection","step-up dosing, Dose and frequency according to the protocol",[9,15,18,21],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Nian","CONTACT","021-50805989-08324","nianhanli@genrixbio.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430000","China",{"type":44,"coordinates":45},"Point",[46,47],114.26667,30.58333,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":11,"email":11},"Professor Li","021-027-84397521",{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100619702",false,"NCT07348055","A Study of GR1803 in Systemic Lupus Erythematosus","A Phase Ib\u002FIIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* comfirmed diagnosis of systemic lupus erythematosus\n* SLEDAI-2K≥6分\n* written informed consent and ability to comply with protocol requirements\n* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months\n\nExclusion Criteria:\n\n* with unstable acute and chronic diseases\n* active infection\n* history of malignant tumor within 5 years","ALL","18 Years","60 Years",{"count":65,"type":66},44,"ESTIMATED","INTERVENTIONAL",[69,70],"PHASE1","PHASE2","to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus",[73,74],"Systemic Lupus Erthematosus","Auto Immune Disease",[76,77],"BCMA\u002FCD3 Bispecific Antibody","systemic lupus erythematosus","2026-03-09",{"date":80,"type":81},"2026-03-10","ACTUAL",{"date":83,"type":81},"2026-02-02",{"date":85,"type":66},"2027-12-01",{"name":5,"class":6},1]